NCT02879903 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Amano A, Kuboniwa M, Nakagawa I, Akiyama S, Morisaki I, Hamada S
Prevalence of specific genotypes of Porphyromonas gingivalis fimA and periodontal health status. J Dent Res. 2000 Sep;79(9):1664-8.
Lin X, Wu J, Xie H
Porphyromonas gingivalis minor fimbriae are required for cell-cell interactions. Infect Immun. 2006 Oct;74(10):6011-5.
Zeller I, Hutcherson JA, Lamont RJ, Demuth DR, Gumus P, Nizam N, Buduneli N, Scott DA
Altered antigenic profiling and infectivity of Porphyromonas gingivalis in smokers and non-smokers with periodontitis. J Periodontol. 2014 Jun;85(6):837-44. doi: 10.190
Zhao L, Wu YF, Meng S, Yang H, OuYang YL, Zhou XD
Prevalence of fimA genotypes of Porphyromonas gingivalis and periodontal health status in Chinese adults. J Periodontal Res. 2007 Dec;42(6):511-7.

Prevalence of Porphyromonas Gingivalis Fimbrial Subunit Genotype in Smokers and Nonsmokers After Periodontal Therapy

Clinical trial NCT02879903 - References